226 related articles for article (PubMed ID: 16115050)
21. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
22. Versican overexpression in cutaneous malignant melanoma.
Gambichler T; Kreuter A; Grothe S; Altmeyer P; Brockmeyer NH; Rotterdam S
Eur J Med Res; 2008 Nov; 13(11):500-4. PubMed ID: 19073385
[TBL] [Abstract][Full Text] [Related]
23. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
24. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
25. Oestrogen receptor-beta expression in melanocytic lesions.
Schmidt AN; Nanney LB; Boyd AS; King LE; Ellis DL
Exp Dermatol; 2006 Dec; 15(12):971-80. PubMed ID: 17083364
[TBL] [Abstract][Full Text] [Related]
26. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
27. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
Brychtova S; Bezdekova M; Brychta T; Tichy M
Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
[TBL] [Abstract][Full Text] [Related]
28. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
Touab M; Arumi-Uría M; Barranco C; Bassols A
Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
[TBL] [Abstract][Full Text] [Related]
29. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
30. Nucleolin protein expression in cutaneous melanocytic lesions.
Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
[TBL] [Abstract][Full Text] [Related]
31. Expression of dicarbonyl/L-xylulose reductase (DCXR) in human skin and melanocytic lesions: morphological studies supporting cell adhesion function of DCXR.
Cho-Vega JH; Vega F; Schwartz MR; Prieto VG
J Cutan Pathol; 2007 Jul; 34(7):535-42. PubMed ID: 17576332
[TBL] [Abstract][Full Text] [Related]
32. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
[TBL] [Abstract][Full Text] [Related]
34. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
35. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas.
Hussein MR; Roggero E; Sudilovsky EC; Tuthill RJ; Wood GS; Sudilovsky O
Am J Dermatopathol; 2001 Aug; 23(4):308-14. PubMed ID: 11481522
[TBL] [Abstract][Full Text] [Related]
36. Myeloid leukemia-1 expression in benign and malignant melanocytic lesions.
Wong RP; Khosravi S; Martinka M; Li G
Oncol Rep; 2008 Apr; 19(4):933-7. PubMed ID: 18357378
[TBL] [Abstract][Full Text] [Related]
37. Cytoplasmic beta-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis?
De Panfilis G; Ferrari D; Santoro S; Ricci R; Lombardi M; Pedrazzi G; Pepe C; Cortelazzi C; Santini M
Br J Dermatol; 2009 Mar; 160(3):600-8. PubMed ID: 19183173
[TBL] [Abstract][Full Text] [Related]
38. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
39. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi.
Park HS; Park CH; Choi BR; Lim MS; Heo SH; Kim CH; Kang SG; Whang KU; Cho MK
J Cutan Pathol; 2009 May; 36(5):511-6. PubMed ID: 19476517
[TBL] [Abstract][Full Text] [Related]
40. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
Giehl KA; Nägele U; Volkenandt M; Berking C
J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
